Hong Kong
· Delayed Price · Currency is HKD RemeGen Company Description
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.
Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.
In addition, the company’s products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy.
RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People’s Republic of China.
| Country | China |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,615 |
| CEO | Jianmin Fang |
Contact Details
Address: 58 Middle Beijing Road Yantai China | |
| Phone | 86 53 56357 3672 |
| Website | remegen.com |
Stock Details
| Ticker Symbol | 9995 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000048G6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jianmin Fang | Co-Founder, Chief Executive Officer, GM, Member of Scientific Advisory Board and Executive Director |
| Weidong Wang | Co-Founder and Executive Chairman |
| Shaojing Tong | Chief Financial Officer and Joint Company Secretary |
| Dr. Ruyi He M.D. | Chief Medical Officer, Member of Scientific Advisory Board and Executive Director |
| Jian Lin | Executive Director |
| Kaisheng Huang | Chief Operating Officer |
| Dr. Marie Zhu | Chief Technical Officer |
| Dr. Zhulun Wang | Chief Scientific Officer |
| Daniel R. Ross | Chief Business Officer |
| Dr. Xiaoming Yang Ph.D. | Chief Manufacturing Officer |